Experimental Drug Likely Saved Ebola Patients
On July 30, the Defense Threat Reduction Agency, an arm of the military responsible for any chemical, biological, radiological, nuclear and high-yield explosive threats, allotted additional funding to MAPP Biopharmaceutical due to "promising results."
On Thursday, Dr. Kent Brantly thought he was going to die. It was the ninth day since the American missionary worker came down sick with Ebola in Liberia. His condition worsening by the minute, Brantly called his wife to say goodbye. Thankfully, the call was premature.
Brantly is back on his feet -- literally -- after receiving a last-ditch, highly experimental drug. Another American missionary with Ebola got the same.
Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected to arrive in Atlanta on Tuesday.
Read the full story here:
Source: CNN
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
Promising Early Efgartigimod Response Data for Generalized Myasthenia GravisSeptember 18th 2025
Iron Dysregulation Linked to MS Progression, Review FindsSeptember 18th 2025
Metabolic Issues More Common in Patients With HIVSeptember 18th 2025
Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction RateSeptember 18th 2025
